Clinical Trial Update: Bone Mineral Density in Human Immunodeficiency Virus Type 1 (HIV-1)-Infected Adult Subjects Switching From a Tenofovir Regimen to a Dolutegravir Plus Rilpivirine Regimen [Phase 3]

View source ↗

Summary

A Phase 3 trial evaluating bone mineral density in HIV-1–infected adults who switch from tenofovir to a dolutegravir plus rilpivirine regimen; results completed…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• HIV Infection

Drugs mentioned

• Dolutegravir (dolutegravir)
• Tenofovir (Tenofovir)
• rilpivirine (rilpivirine)

Snippet

Sponsor: ViiV Healthcare | Conditions: HIV Infections | Phase 3 | Status: COMPLETED | Results posted: 2017-10-20